Investigation of the First Seven Reported Cases of Candida auris, a Globally Emerging Invasive, Multidrug-Resistant Fungus - United States, May 2013-August 2016.
Candida auris, an emerging fungus that can cause invasive infections, is associated with high mortality and is often resistant to multiple antifungal drugs. C. auris was first described in 2009 after being isolated from external ear canal discharge of a patient in Japan (1). Since then, reports of C. auris infections, including bloodstream infections, have been published from several countries, including Colombia, India, Israel, Kenya, Kuwait, Pakistan, South Africa, South Korea, Venezuela, and the United Kingdom (2-7). To determine whether C. auris is present in the United States and to prepare for the possibility of transmission, CDC issued a clinical alert in June 2016 informing clinicians, laboratorians, infection control practitioners, and public health authorities about C. auris and requesting that C. auris cases be reported to state and local health departments and CDC (8). This report describes the first seven U.S. cases of C. auris infection reported to CDC as of August 31, 2016. Data from these cases suggest that transmission of C. auris might have occurred in U.S. health care facilities and demonstrate the need for attention to infection control measures to control the spread of this pathogen.
Snigdha
S
Vallabhaneni
Alex
A
Kallen
Sharon
S
Tsay
Nancy
N
Chow
Rory
R
Welsh
Janna
J
Kerins
Sarah K
SK
Kemble
Massimo
M
Pacilli
Stephanie R
SR
Black
Emily
E
Landon
Jessica
J
Ridgway
Tara N
TN
Palmore
Adrian
A
Zelzany
Eleanor H
EH
Adams
Monica
M
Quinn
Sudha
S
Chaturvedi
Jane
J
Greenko
Rafael
R
Fernandez
Karen
K
Southwick
E Yoko
EY
Furuya
David P
DP
Calfee
Camille
C
Hamula
Gopi
G
Patel
Patricia
P
Barrett
Patricia
P
Lafaro
Elizabeth L
EL
Berkow
Heather
H
Moulton-Meissner
Judith
J
Noble-Wang
Ryan P
RP
Fagan
Brendan R
BR
Jackson
Shawn R
SR
Lockhart
Anastasia P
AP
Litvintseva
Tom M
TM
Chiller
D000935:Antifungal Agents / Q000494:pharmacology / Q000627:therapeutic use; D002175:Candida / Q000187:drug effects / Q000302:isolation & purification*; D002177:Candidiasis / Q000175:diagnosis* / Q000188:drug therapy / Q000382:microbiology*; D021821:Communicable Diseases, Emerging; D026141:Drug Resistance, Multiple, Fungal; D017809:Fatal Outcome; D014943:Global Health; D006801:Humans; D014481:United States
D000935:Antifungal Agents